Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173392 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
A Phase 1 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT02173392 is a Phase 1 study that has completed, run by Bausch Health Americas. The registered enrollment target is 145 participants.
The verdict
NCT02173392, a Phase 1 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
A healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single dose of Brodalumab vs. two doses of Brodalumab
Interventions
- DRUG Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02173392
The ClinicalTrials.gov registry entry for NCT02173392 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brodalumab is the first listed.
NCT02173392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02173392 about?
NCT02173392 is a clinical study titled "A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab". A healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single dose of Brodalumab vs. two doses of Brodalumab
What is the current status of trial NCT02173392?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2014-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02173392?
The interventions under investigation include: Brodalumab (DRUG).
Who is sponsoring clinical trial NCT02173392?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.